{"protocolSection": {"identificationModule": {"nctId": "NCT00125853", "orgStudyIdInfo": {"id": "NPSW02"}, "organization": {"fullName": "Imperial College London", "class": "OTHER"}, "briefTitle": "The Effect of Nebivolol on Insulin Sensitivity", "officialTitle": "A Trial to Compare the Effects of Nebivolol Versus Atenolol on Various Cardiovascular Measurements Including Insulin Sensitivity"}, "statusModule": {"statusVerifiedDate": "2019-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-07-29", "studyFirstSubmitQcDate": "2005-07-29", "studyFirstPostDateStruct": {"date": "2005-08-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-06-12", "resultsFirstSubmitQcDate": "2019-11-21", "resultsFirstPostDateStruct": {"date": "2019-12-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-11-21", "lastUpdatePostDateStruct": {"date": "2019-12-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Imperial College London", "class": "OTHER"}, "collaborators": [{"name": "Foundation for Circulatory Health", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic.", "detailedDescription": "Retrospective studies of treated hypertensive cohorts have strongly implicated beta blocker therapy as increasing the risk of developing new-onset diabetes. This has led to the latest British Hypertension Society guidelines advising caution when using beta blockers particularly in combination with thiazide-like diuretics. However the National Institute of Clinical Excellence recommends beta-blocker + thiazide combinations as the treatment of choice in patients who are not at increased risk of developing diabetes. Nebivolol is a newer class of beta blocker. Some studies in diabetic hypertensive patients have suggested that nebivolol does not impair insulin sensitivity. The aim of this study is to compare the effect on insulin sensitivity of nebivolol versus atenolol, both in combination with a thiazide-like diuretic, in a group of non-diabetic hypertensive patients."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["blood pressure", "insulin sensitivity", "beta blockers", "randomised double blind crossover trial"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 54, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "atenolol 25mg daily", "type": "EXPERIMENTAL", "description": "atenolol 25mg daily", "interventionNames": ["Drug: Atenolol"]}, {"label": "nebivolol 2.5mg daily", "type": "ACTIVE_COMPARATOR", "description": "nebivolol 2.5mg daily", "interventionNames": ["Drug: Nebivolol"]}], "interventions": [{"type": "DRUG", "name": "Nebivolol", "description": "Nebivolol 2.5mg daily", "armGroupLabels": ["nebivolol 2.5mg daily"]}, {"type": "DRUG", "name": "Atenolol", "description": "Atenolol 25mg daily", "armGroupLabels": ["atenolol 25mg daily"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Insulin Sensitivity Index (ISI)", "description": "Patients were asked to fast for a minimum of 12 hours prior to each oral glucose tolerance test (OGTT). Venous blood was withdrawn for insulin and glucose analysis, 15 minutes and immediately prior to, and 30, 60, 90 and 120 minutes following an oral glucose load. For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing.\n\nFor each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing.", "timeFrame": "Baseline, 15, 30, 60, 90, 120m following oral glucose load, at baseline and at the end of each phase(8 weeks treatment"}], "secondaryOutcomes": [{"measure": "24 Hour Systolic Blood Pressure", "description": "The 24-h Ambulatory Blood Pressure Monitoring (ABPM) was recorded at the beginning and end of each beta-blocker treatment period. BP was automatically recorded for 24 h at 30 min intervals. The time periods from 0700h to 2200h and from 2200h to 0700h were defined as daytime and night-time, respectively.", "timeFrame": "Before and after 8 weeks of treatment"}, {"measure": "Total Cholesterol", "description": "Fasting blood samples were taken at the beginning and end of each treatment period.", "timeFrame": "Before and after 8 weeks of treatment"}, {"measure": "HbA1c", "description": "Fasting blood samples were taken at the beginning and end of each treatment period.", "timeFrame": "Before and after 8 weeks of treatment"}, {"measure": "BMI", "description": "Body weights and heights were taken at the beginning and end of each treatment period.", "timeFrame": "Before and after 8 weeks of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females aged 18 or above\n* Blood pressure that meets any of the three following criteria:\n* BP should be \\<140/85 mmHg on a maximum of two anti-hypertensive drugs\n\nExclusion Criteria:\n\n* contraindications to beta-blockade\n* contraindications to thiazide use\n* if there was a history of asthma, diabetes, heart failure, bradycardia, atrial fibrillation, AV conduction disturbances\n* concurrent treatment with verapamil \\& dilitiazem\n* childbearing women\n* compelling indication for treatment with a beta blocker\n* any condition that will interfere with the treatment or the patient's ability to complete the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Neil R Poulter", "affiliation": "Imperial College London", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Imperial College London", "city": "Paddington", "state": "London", "zip": "W2 1PG", "country": "United Kingdom", "geoPoint": {"lat": 51.51558, "lon": -0.1763}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "First is Atenolol Followed by Nebivolol (AN)", "description": "Atenolol 25mg daily for 8 weeks, followed by a 4-week wash-out period, then nebivolol 2.5 mg daily for 8 weeks"}, {"id": "FG001", "title": "First is Nebivolol Followed by Atenolol (NA)", "description": "Nebivolol 2.5mg daily for 8 weeks, followed by a 4-week wash-out period, then atenolol 25 mg daily for 8 weeks"}], "periods": [{"title": "Wash-out (4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "First Intervention (8 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Wash-out (4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "7"}]}]}, {"title": "Second Intervention (8 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "Crossover study design all participants will receive both treatments"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "54"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.1", "spread": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}]}]}]}, {"title": "BMI", "description": "kg/m2", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.2", "spread": "6.7"}]}]}]}, {"title": "Current Smoker", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}]}, {"title": "Ex-smoker", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}]}, {"title": "Systolic Blood Pressure (SBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "129.4", "spread": "13.2"}]}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "81.3", "spread": "9.0"}]}]}]}, {"title": "Heart Rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "bpm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71.1", "spread": "8.9"}]}]}]}, {"title": "HBa1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.7", "spread": "0.7"}]}]}]}, {"title": "Total Cholesterol", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.1", "spread": "1.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Insulin Sensitivity Index (ISI)", "description": "Patients were asked to fast for a minimum of 12 hours prior to each oral glucose tolerance test (OGTT). Venous blood was withdrawn for insulin and glucose analysis, 15 minutes and immediately prior to, and 30, 60, 90 and 120 minutes following an oral glucose load. For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing.\n\nFor each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing.", "populationDescription": "Patients with mild-to-moderate essential hypertension, aged 18 years or above, with blood pressure controlled to \\<140/85 mmHg on a maximum of two antihypertensive drugs, were recruited from the Peart-Rose Hypertension clinic at St Mary's Hospital in West London and from local general practices.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "factor", "timeFrame": "Baseline, 15, 30, 60, 90, 120m following oral glucose load, at baseline and at the end of each phase(8 weeks treatment", "groups": [{"id": "OG000", "title": "Atenolol", "description": "Participants received Atenolol 25mg daily for 8 weeks"}, {"id": "OG001", "title": "Nebivolol", "description": "Participants received Nebivolol 2.5mg daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"title": "Before", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.36", "lowerLimit": "50.8", "upperLimit": "116.9"}, {"groupId": "OG001", "value": "80.70", "lowerLimit": "52.6", "upperLimit": "114.7"}]}]}, {"title": "After", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.47", "lowerLimit": "50.6", "upperLimit": "144.9"}, {"groupId": "OG001", "value": "81.54", "lowerLimit": "50.9", "upperLimit": "114.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing treatment effects on ISI", "nonInferiorityType": "OTHER", "nonInferiorityComment": "Linear Mixed effect Modelling, adjusted for baseline values and period effect\n\nDifference of LSMeans treatment effect (SE) = 0.05 (0.09)", "pValue": "0.60", "statisticalMethod": "Linear Mixed effect Modelling, adjusted"}]}, {"type": "SECONDARY", "title": "24 Hour Systolic Blood Pressure", "description": "The 24-h Ambulatory Blood Pressure Monitoring (ABPM) was recorded at the beginning and end of each beta-blocker treatment period. BP was automatically recorded for 24 h at 30 min intervals. The time periods from 0700h to 2200h and from 2200h to 0700h were defined as daytime and night-time, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Before and after 8 weeks of treatment", "groups": [{"id": "OG000", "title": "Atenolol", "description": "Participants received Atenolol 25mg daily for 8 weeks"}, {"id": "OG001", "title": "Nebivolol", "description": "Participants received Nebivolol 2.5mg daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"title": "SBP before", "categories": [{"measurements": [{"groupId": "OG000", "value": "128.4", "spread": "9.7"}, {"groupId": "OG001", "value": "130.4", "spread": "9.5"}]}]}, {"title": "SBP after", "categories": [{"measurements": [{"groupId": "OG000", "value": "117.2", "spread": "9.2"}, {"groupId": "OG001", "value": "121.2", "spread": "8.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing treatment effects on ABPM", "nonInferiorityType": "OTHER", "nonInferiorityComment": "Linear Mixed effect Model, adjusted for baseline values and period effect\n\nDifference of LSMeans treatment effect (SE)\n\n= -2.59 (1.34)", "pValue": "0.06", "statisticalMethod": "Linear Mixed effect Model, adjusted for"}]}, {"type": "SECONDARY", "title": "Total Cholesterol", "description": "Fasting blood samples were taken at the beginning and end of each treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Before and after 8 weeks of treatment", "groups": [{"id": "OG000", "title": "Atenolol", "description": "Participants received Atenolol 25mg daily for 8 weeks"}, {"id": "OG001", "title": "Nebivolol", "description": "Participants received Nebivolol 2.5mg daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"title": "Before", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "1.0"}, {"groupId": "OG001", "value": "5.1", "spread": "0.9"}]}]}, {"title": "After", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.9", "spread": "1.0"}, {"groupId": "OG001", "value": "5.1", "spread": "0.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing treatment effects on total cholesterol", "nonInferiorityType": "OTHER", "nonInferiorityComment": "Linear Mixed effect Model, adjusted for baseline values and period effect\n\nDifference of LSMeans treatment effect (SE)\n\n= -0/09 (0.14)", "pValue": "0.51", "statisticalMethod": "Linear Mixed effect Modelling, adjusted"}]}, {"type": "SECONDARY", "title": "HbA1c", "description": "Fasting blood samples were taken at the beginning and end of each treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Before and after 8 weeks of treatment", "groups": [{"id": "OG000", "title": "Atenolol", "description": "Participants received Atenolol 25mg daily for 8 weeks"}, {"id": "OG001", "title": "Nebivolol", "description": "Participants received Nebivolol 2.5mg daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"title": "Before", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7", "spread": "0.8"}, {"groupId": "OG001", "value": "5.7", "spread": "0.8"}]}]}, {"title": "After", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7", "spread": "0.4"}, {"groupId": "OG001", "value": "5.7", "spread": "0.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing treatment effects on HbA1c", "nonInferiorityType": "OTHER", "nonInferiorityComment": "Linear Mixed effect Model, adjusted for baseline values and period effect\n\nDifference of LSMeans treatment effect (SE) =0.02 (0.03)", "pValue": "0.48", "statisticalMethod": "Linear Mixed effect Modelling, adjusted"}]}, {"type": "SECONDARY", "title": "BMI", "description": "Body weights and heights were taken at the beginning and end of each treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg/m^2", "timeFrame": "Before and after 8 weeks of treatment", "groups": [{"id": "OG000", "title": "Atenolol", "description": "Participants received Atenolol 25mg daily for 8 weeks"}, {"id": "OG001", "title": "Nebivolol", "description": "Participants received Nebivolol 2.5mg daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"title": "Before", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.1", "spread": "4.6"}, {"groupId": "OG001", "value": "28.2", "spread": "4.7"}]}]}, {"title": "After", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.0", "spread": "4.4"}, {"groupId": "OG001", "value": "28.3", "spread": "4.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing treatment effects on BMI", "nonInferiorityType": "OTHER", "nonInferiorityComment": "Linear Mixed effect Model, adjusted for baseline values and period effect\n\nDifference of LSMeans treatment effect (SE)\n\n= -0.21(0.13)", "pValue": "0.09", "statisticalMethod": "Linear Mixed effect Modelling, adjusted"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "32 weeks", "eventGroups": [{"id": "EG000", "title": "Atenolol 25mg Daily", "description": "atenolol 25mg daily\n\nAtenolol: Atenolol 25mg daily", "deathsNumAffected": 0, "deathsNumAtRisk": 54, "seriousNumAffected": 0, "seriousNumAtRisk": 54, "otherNumAffected": 0, "otherNumAtRisk": 54}, {"id": "EG001", "title": "Nebivolol 2.5mg Daily", "description": "nebivolol 2.5mg daily\n\nNebivolol: Nebivolol 25mg daily", "deathsNumAffected": 0, "deathsNumAtRisk": 54, "seriousNumAffected": 0, "seriousNumAtRisk": 54, "otherNumAffected": 0, "otherNumAtRisk": 54}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Professor Neil Poulter", "organization": "Imperial College London", "email": "n.poulter@imperial.ac.uk", "phone": "+44 2075943445"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000007333", "term": "Insulin Resistance"}, {"id": "D000006967", "term": "Hypersensitivity"}], "ancestors": [{"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000006946", "term": "Hyperinsulinism"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "asFound": "Sensitivity", "relevance": "HIGH"}, {"id": "M10370", "name": "Insulin Resistance", "asFound": "Insulin Sensitivity", "relevance": "HIGH"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M9997", "name": "Hyperinsulinism", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001262", "term": "Atenolol"}, {"id": "D000068577", "term": "Nebivolol"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058665", "term": "Adrenergic beta-1 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M276", "name": "Nebivolol", "asFound": "Opioid Use", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M4568", "name": "Atenolol", "asFound": "Allowing", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}]}}, "hasResults": true}